Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

418 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acceptance and Commitment Therapy for people living with motor neuron disease: an uncontrolled feasibility study.
Gould RL, Rawlinson C, Thompson B, Weeks K, Gossage-Worrall R, Cantrill H, Serfaty MA, Graham CD, McCracken LM, White D, Howard RJ, Bursnall M, Bradburn M, Al-Chalabi A, Orrell R, Chhetri SK, Noad R, Radunovic A, Williams T, Young CA, Dick D, Lawrence V, Goldstein LH, Young T, Ealing J, McLeod H, Williams N, Weatherly H, Cave R, Chiwera T, Pagnini F, Cooper C, Shaw PJ, McDermott CJ; and the COMMEND Collaboration Group. Gould RL, et al. Pilot Feasibility Stud. 2023 Jul 7;9(1):116. doi: 10.1186/s40814-023-01354-7. Pilot Feasibility Stud. 2023. PMID: 37420261 Free PMC article.
Cost-effectiveness of acceptance and commitment therapy for people living with motor neuron disease, and their health-related quality of life.
Keetharuth AD, Gould RL, McDermott CJ, Thompson BJ, Rawlinson C, Bradburn M, Bursnall M, Kumar P, Turton EJ, Tappenden P, White D, Howard RJ, Serfaty MA, McCracken LM, Graham CD, Al-Chalabi A, Goldstein LH, Lawrence V, Cooper C, Young T; COMMEND Collaboration Group. Keetharuth AD, et al. Among authors: al chalabi a. Eur J Neurol. 2024 Apr 25:e16317. doi: 10.1111/ene.16317. Online ahead of print. Eur J Neurol. 2024. PMID: 38660985
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.
UKMND-LiCALS Study Group; Morrison KE, Dhariwal S, Hornabrook R, Savage L, Burn DJ, Khoo TK, Kelly J, Murphy CL, Al-Chalabi A, Dougherty A, Leigh PN, Wijesekera L, Thornhill M, Ellis CM, O'Hanlon K, Panicker J, Pate L, Ray P, Wyatt L, Young CA, Copeland L, Ealing J, Hamdalla H, Leroi I, Murphy C, O'Keeffe F, Oughton E, Partington L, Paterson P, Rog D, Sathish A, Sexton D, Smith J, Vanek H, Dodds S, Williams TL, Steen IN, Clarke J, Eziefula C, Howard R, Orrell R, Sidle K, Sylvester R, Barrett W, Merritt C, Talbot K, Turner MR, Whatley C, Williams C, Williams J, Cosby C, Hanemann CO, Iman I, Philips C, Timings L, Crawford SE, Hewamadduma C, Hibberd R, Hollinger H, McDermott C, Mils G, Rafiq M, Shaw PJ, Taylor A, Waines E, Walsh T, Addison-Jones R, Birt J, Hare M, Majid T. UKMND-LiCALS Study Group, et al. Lancet Neurol. 2013 Apr;12(4):339-45. doi: 10.1016/S1474-4422(13)70037-1. Epub 2013 Feb 27. Lancet Neurol. 2013. PMID: 23453347 Free PMC article. Clinical Trial.
Author Correction: Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.
Michael BD, Dunai C, Needham EJ, Tharmaratnam K, Williams R, Huang Y, Boardman SA, Clark JJ, Sharma P, Subramaniam K, Wood GK, Collie C, Digby R, Ren A, Norton E, Leibowitz M, Ebrahimi S, Fower A, Fox H, Tato E, Ellul MA, Sunderland G, Held M, Hetherington C, Egbe FN, Palmos A, Stirrups K, Grundmann A, Chiollaz AC, Sanchez JC, Stewart JP, Griffiths M, Solomon T, Breen G, Coles AJ, Kingston N, Bradley JR, Chinnery PF, Cavanagh J, Irani SR, Vincent A, Baillie JK, Openshaw PJ, Semple MG; ISARIC4C Investigators; COVID-CNS Consortium; Taams LS, Menon DK. Michael BD, et al. Nat Commun. 2024 Apr 4;15(1):2918. doi: 10.1038/s41467-024-47320-6. Nat Commun. 2024. PMID: 38575615 Free PMC article. No abstract available.
European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD).
Van Damme P, Al-Chalabi A, Andersen PM, Chiò A, Couratier P, De Carvalho M, Hardiman O, Kuźma-Kozakiewicz M, Ludolph A, McDermott CJ, Mora JS, Petri S, Probyn K, Reviers E, Salachas F, Silani V, Tysnes OB, van den Berg LH, Villanueva G, Weber M. Van Damme P, et al. Among authors: al chalabi a. Eur J Neurol. 2024 Mar 12:e16264. doi: 10.1111/ene.16264. Online ahead of print. Eur J Neurol. 2024. PMID: 38470068
Dyspnea (breathlessness) in amyotrophic lateral sclerosis/motor neuron disease: prevalence, progression, severity, and correlates.
Young CA, Chaouch A, Mcdermott CJ, Al-Chalabi A, Chhetri SK, Talbot K, Harrower T, Orrell RW, Annadale J, Hanemann CO, Scalfari A, Tennant A, Mills R; TONIC-ALS STUDY GROUP. Young CA, et al. Among authors: al chalabi a. Amyotroph Lateral Scler Frontotemporal Degener. 2024 Mar 11:1-11. doi: 10.1080/21678421.2024.2322545. Online ahead of print. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38465877
Improving the measurement properties of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): deriving a valid measurement total for the calculation of change.
Young CA, Chaouch A, Mcdermott CJ, Al-Chalabi A, Chhetri SK, Talbot K, Malaspina A, Mills R, Tennant A. Young CA, et al. Among authors: al chalabi a. Amyotroph Lateral Scler Frontotemporal Degener. 2024 May;25(3-4):400-409. doi: 10.1080/21678421.2024.2322539. Epub 2024 Mar 1. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38426231 Free article.
What is the extent of reliability and validity evidence for screening tools for cognitive and behavioral change in people with ALS? A systematic review.
Didcote L, Vitoratou S, Al-Chalabi A, Goldstein LH. Didcote L, et al. Among authors: al chalabi a. Amyotroph Lateral Scler Frontotemporal Degener. 2024 Feb 28:1-15. doi: 10.1080/21678421.2024.2314063. Online ahead of print. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38415696 Free PMC article. Review.
The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials.
Genge A, Cedarbaum JM, Shefner J, Chio A, Al-Chalabi A, Van Damme P, McDermott C, Glass J, Berry J, van Eijk RPA, Fournier C, Grosskreutz J, Andrews J, Bertone V, Bunte TM, Couillard M, Cummings C, Kittle G, Polzer J, Salmon K, Straub C, van den Berg LH. Genge A, et al. Among authors: al chalabi a. Amyotroph Lateral Scler Frontotemporal Degener. 2024 May;25(3-4):382-387. doi: 10.1080/21678421.2024.2320880. Epub 2024 Feb 23. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38396337 Free article.
418 results